Immunomedics
ClosedNext-generation ADC therapies for hard-to-treat cancers.
Morris Plains, United States · Founded 2004 · $459.0M raised
- Headquarters
- Morris Plains, New Jersey
- Employees
- 201–500
- Founded
- 2004
- Business Model
- B2B
- Website
- immunomedics.com
- Total Funding
- $459.0M
- Last Round
- $459.0M Private EquityMay 2020
- Rounds
- 1
About
Immunomedics was a clinical-stage biopharmaceutical company pioneering next-generation antibody-drug conjugate (ADC) technology for the targeted treatment of cancer, including triple-negative breast cancer and other solid tumors. Its lead drug, Trodelvy (sacituzumab govitecan), received FDA approval before the company was acquired by Gilead Sciences for $21 billion in 2020.
Summary
Immunomedics is a biotechnology company based in Morris Plains, United States, founded in 2004. It has raised $459.0M in total across 1 round, most recently a $459.0M Private Equity round in May 2020. Investors include Gilead Sciences.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Sep 2020
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...